Two Injections a Year Can Prevent HIV. Will Nigeria Make Them Easy to Get?

A prevention medicine measured in months, not mornings

For years, the most familiar form of pre exposure prophylaxis, or PrEP, has been a tablet taken regularly by someone who does not have HIV but may be exposed to it. When used correctly, oral PrEP is highly effective. Its weakness is not the science. It is that real life can make a daily routine difficult.

Tablets can be forgotten. They can be seen by a partner, roommate or relative who begins asking questions. A person may run out between clinic visits, avoid a refill because of stigma or simply decide that a risk which feels distant today does not justify another pill tonight.

Lenacapavir changes the rhythm. It is a long acting medicine administered by injection about once every six months. The World Health Organization now recommends it as an additional PrEP choice. For somebody who finds daily tablets difficult, two planned appointments a year can feel radically simpler.

But lenacapavir is not a vaccine, a cure or a treatment to improvise without medical supervision. It is an antiretroviral medicine for people confirmed not to have HIV before starting PrEP. HIV testing and clinical assessment remain essential, and the injection schedule matters.

The trial results changed the argument

The excitement rests on unusually strong evidence. In the PURPOSE 1 trial, involving cisgender women in South Africa and Uganda, no HIV infections were observed among participants assigned to twice yearly lenacapavir during the primary analysis. The trial was stopped early for efficacy so participants could be offered the long acting option.

PURPOSE 2 extended the evidence to cisgender men, transgender women, transgender men and gender nonbinary people across several countries. Two infections occurred among participants assigned to lenacapavir, but the incidence was dramatically lower than the estimated background incidence and lower than in the comparison group receiving daily oral PrEP.

Those findings do not mean infection is impossible. No prevention method should be described to an individual as a personal guarantee. They do mean that lenacapavir performed exceptionally well across two large and different study populations, giving regulators and WHO enough evidence to treat it as a major new prevention option.

The medicine works by interfering with the HIV capsid, a protein shell the virus needs at several stages of its life cycle. The public health advantage is easier to understand than the molecular one: protection lasts long enough that prevention no longer has to be remembered every morning.

Nigeria is preparing before the queue forms

On 17 September 2026, WHO's Nigeria office reported that the country was expanding PrEP training for health workers. A national training of trainers held in May brought together 80 people from 32 states and the Federal Capital Territory. They included doctors, nurses, pharmacists, programme officers, academics and community representatives.

The plan is for those participants to train other providers in their states and facilities. Follow on training had already reached 90 people in Benue, 118 in Taraba and 26 in Ekiti, according to WHO. The curriculum covers counselling, assessing who may benefit, explaining different PrEP choices and supporting people who choose to continue.

This matters because a medicine cannot become a service by arriving in a procurement document. Somebody must be able to explain it without judgement, test safely, administer it correctly, manage follow up and answer the questions that will appear once people have heard the headline but not the details.

Nigeria's National HIV Prevention Plan 2026 to 2030 includes oral PrEP and longer acting options. WHO's wording is careful: the country is preparing its workforce for a wider range of choices, subject to national guidance, approval and implementation plans. Preparation should not be confused with universal availability. A trained provider is a beginning, not proof that every eligible person can obtain the product today.

The greatest advantage may be privacy

The usual explanation for long acting PrEP is adherence. Fewer doses create fewer opportunities to forget. That is true, but it misses something more human. For some people, the important advantage will be privacy.

A bottle of tablets can disclose a decision a person was not ready to discuss. Taking a pill may invite questions from a controlling partner. Returning frequently to a familiar clinic can feel risky in a community where HIV services are still surrounded by assumptions. A discreet appointment twice a year may reduce some of that burden.

Long acting does not mean no contact with healthcare. People still need counselling and HIV testing before injections. They need a reliable way to return on schedule and somewhere to go if they experience side effects or their circumstances change. A missed appointment can create a period in which drug levels fall, which is one reason follow up and alternative prevention plans matter.

Choice is therefore the breakthrough, not replacement. Some people will prefer tablets they can control themselves. Others may choose injectable cabotegravir, a different long acting option. Condoms remain important because PrEP does not prevent pregnancy or other sexually transmitted infections. A good programme expands the menu without turning one product into the new compulsory answer.

A breakthrough can still reproduce inequality

The danger is familiar. A technology can be celebrated globally while reaching the people with the easiest access first. Large hospitals in major cities may develop expertise while rural facilities wait. Donor supported programmes may serve selected populations while others discover that the medicine exists but not where they live. A product described as transformative may still be unaffordable to someone paying privately.

International access arrangements are beginning to grow. The Global Fund and partners have announced plans to expand lenacapavir access across high burden countries, and generic manufacturers are expected to play a larger role. Those agreements matter, but the numbers must be judged against the scale of need, not the excitement of a launch.

The key Nigerian questions are practical. Which regulator has authorised which use? Which national guideline applies? Who is eligible? Which facilities will offer it? Who pays for testing and administration? What happens when a client moves to another state? Will stock be continuous enough that people are not asked to begin a schedule the system cannot maintain?

If those answers are difficult to find, misinformation will fill the gap. People will encounter invented prices, fake suppliers, unqualified injectors and promises that turn a highly effective medicine into a supposed vaccine. Clear public communication is therefore part of safety, not an optional media exercise.

What Nigeria must get right

Nigeria already knows where some of the opportunities are. A 2025 national PrEP assessment identified scope to integrate prevention into antenatal care, sexual and reproductive health services, sexually transmitted infection care and services for people affected by gender based violence. Those are points where a conversation can happen as part of ordinary healthcare rather than behind a door marked only for HIV.

Integration must still protect consent and confidentiality. A pregnant woman should be offered information, not pressured. A young person should not be shamed for asking. Key populations should not have to trade safety for access. The quality of the encounter will determine whether people return and whether they tell others that the service can be trusted.

The rollout should also be measured honestly. Counting injections is not enough. Programmes need to know who was assessed, who started, who returned on time, who discontinued and why. They need to see whether access is concentrated in a few cities and whether women, young people and marginalised communities are receiving the choices described in national plans.

• Publish a clear national implementation timetable and an official list of participating facilities.
• Train providers beyond tertiary hospitals and support confidential services close to where people live.
• Protect voluntary choice between oral PrEP, long acting options, condoms and other appropriate prevention tools.
• Fund HIV testing, counselling and follow up as part of the product, not as invisible extras.
• Track continuation and missed injections without punishing or stigmatising clients.
• Communicate price and eligibility publicly so fake sellers cannot define the market first.

Who this does and does not help

Lenacapavir for PrEP is intended for people who do not have HIV and could benefit from protection before exposure. It is not a substitute for antiretroviral treatment for a person already living with HIV. That distinction is one reason testing is so important before starting and while continuing long acting PrEP.

It also does not prevent gonorrhoea, syphilis, chlamydia or pregnancy. Depending on a person's circumstances, a clinician may recommend condoms, contraception, vaccination, screening or other care alongside PrEP. Prevention works best when the person understands what each tool can and cannot do.

Nor is lenacapavir the only meaningful HIV story. Treatment remains prevention too. A person living with HIV who takes effective treatment and maintains an undetectable viral load does not sexually transmit the virus. Testing, treatment, viral suppression, condoms, PrEP and respectful sexual health services are complementary parts of the same response.

The science is ready. The system now has to be.

There was a time when preventing HIV with two injections a year would have sounded implausible. The medicine now exists. The evidence is strong. WHO has issued guidance. Nigeria has placed longer acting prevention inside its national planning and begun expanding the workforce expected to deliver it.

That progress deserves attention. It also deserves scrutiny. The history of global health contains too many breakthroughs whose benefits arrived late, unevenly or only after preventable infections had continued for years.

Nigeria's success will not be measured by how often lenacapavir appears in speeches. It will be measured by whether a person can ask about it without shame, receive accurate information, obtain it through a safe and affordable service, and return six months later to find the next dose waiting.

Two injections a year can transform HIV prevention. Whether they transform HIV prevention in Nigeria is now a question for the health system, the budget and the institutions responsible for turning a remarkable medicine into ordinary access.